Alzamend Neuro, Inc. (ALZN) vs COSCIENS Biopharma Inc. (CSCIF)

Alzamend Neuro, Inc. and COSCIENS Biopharma Inc. are both Biotechnology companies. Alzamend Neuro, Inc. and COSCIENS Biopharma Inc. are of similar size ($8.8M and $8.6M). Alzamend Neuro, Inc. has negative trailing earnings, so its P/E is not meaningful; COSCIENS Biopharma Inc. trades at 1.0×. COSCIENS Biopharma Inc. has the higher net margin (75.1% vs 0.00%) and the lower return on invested capital (−40.6% vs 0.00%). Across the 13 metrics below, COSCIENS Biopharma Inc. leads on 8 and Alzamend Neuro, Inc. on 5.

Valuation

Metric ALZN CSCIF Biotechnology median
P/E n/m 0.97 7.88
P/S n/m 0.73 11.47
P/B 1.41 0.43 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 0.13 10.73
Earnings yield (125.68%) 103.12% (28.84%)
Free cash flow yield (87.16%) (48.39%) (23.03%)

Profitability

Metric ALZN CSCIF Biotechnology median
Gross margin 0.00% 46.48% 65.16%
Operating margin 0.00% (71.13%) 0.00%
Net margin 0.00% 75.11% 0.00%
Free cash flow margin 0.00% (40.36%) 0.00%
Return on equity (163.23%) 59.74% (57.72%)
Return on assets (122.36%) 28.24% (49.22%)
Return on invested capital 0.00% (40.56%) 0.00%

Growth

Metric ALZN CSCIF Biotechnology median
Revenue growth (TTM) — (3.02%) 5.64%
EPS growth (last fiscal year) 76.77% 44.86% —
Revenue growth, 5-year CAGR — 15.47% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALZN CSCIF Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.01 4.33 4.73
Net debt to EBITDA 0.08 0.78 0.96

Dividend

Metric ALZN CSCIF Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric ALZN CSCIF Biotechnology median
Market cap 8.78m 8.57m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack